Trial 3P-17-2


A Randomized Phase 3 Study of AM0010 in Combination with FOLFOX Compared with FOLFOX Alone as Second-line Therapy in Patients with Metastatic Pancreatic Cancer that has Progressed During or Following a First-Line Gemcitabine Containing Regimen

Type: Treatment
Phase: Phase III
Status: Not Open (Closed)
Treatments: Biological Response Modifier, Chemotherapy: Systemic
Randomized: Yes
USC Satellite Location: None
Defintions of terms and FAQ about clinical trials.
Trial Leaders/Researchers:  Heinz Josef Lenz, M.D.
Other Trial Staff:  Ramona Lujan, Coordinator, Fahim Raian, D.M., Jiayi Jiang, D.M., Raluca Agafitei, Coordinator, Melissa Wallman, Coordinator, Yanli Wang, D.M., Rabia Rehman, Coordinator, Apoorva Vishwanath, D.M.

Staff may log in to see study documents.

Click here to see trial eligibility criteria and further details at ClinicalTrials.gov





For further information on a study, please contact the Clinical Investigation Support Office at (323) 865-0451, or clinical.trials@med.usc.edu.

To schedule a consultation with the hospital, please call our New Patient Referrals Office at (323) 865-3300.